Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalent Inc
(NY:
CTLT
)
55.37
+0.12 (+0.22%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalent Inc
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Markets Fall As Investors Weigh March CPI Report
April 12, 2022
U.S. indices sold off to close Tuesday’s session following earlier strength. Investors reacted to the March CPI report and continue to assess Fed rate hike concerns. While...
Via
Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
March 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Catalent, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum
March 18, 2022
From
Catalent, Inc.
Via
Business Wire
Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand
March 03, 2022
Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug. Novo Nordisk aims to...
Via
Benzinga
Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance
February 01, 2022
Catalent Inc (NYSE: CTLT) has reported Q2 FY22 sales of $1.
Via
Benzinga
Expert Ratings For Catalent
January 27, 2022
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter:
Via
Benzinga
Expert Ratings For Catalent
November 03, 2021
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within ...
Via
Benzinga
Executives Sell More Than $210M Of 5 Stocks
February 09, 2022
Spanish stocks traded higher this morning, with the IBEX 35 Index surging to the strongest level in over two weeks. Investors, meanwhile, focused on some notable insider trades....
Via
Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
February 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Catalent, Inc. Reports Second Quarter Fiscal 2022 Results
February 01, 2022
From
Catalent, Inc.
Via
Business Wire
A Bearish Sign Appears On Catalent's Chart
January 31, 2022
If history is any guide, there may be trouble ahead for shares of Catalent (NYSE:CTLT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Via
Benzinga
Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast
January 21, 2022
From
Catalent, Inc.
Via
Business Wire
This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut
January 20, 2022
John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change.
Via
Investor's Business Daily
FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report
January 14, 2022
Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for...
Via
Benzinga
Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022
January 05, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Catalent, Inc.
Via
Business Wire
A Look Into Catalent's Price Over Earnings
December 30, 2021
In the current session, Catalent Inc. (NYSE:CTLT) is trading at $128.13, after a 0.1% increase. Over the past month, the stock increased by 0.34%, and in the past...
Via
Benzinga
Catalent, Inc. to Present at the Stephens Annual Investment Conference
November 23, 2021
From
Catalent, Inc.
Via
Business Wire
Catalent, inc (CTLT) Q1 2022 Earnings Call Transcript
November 02, 2021
CTLT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
December 16, 2021
Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE:
Via
Benzinga
Catalent, Inc. Reports First Quarter Fiscal 2022 Results
November 02, 2021
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast
October 20, 2021
From
Catalent, Inc.
Via
Business Wire
Chair And CEO Of Catalent Trades $22M In Company Stock
October 06, 2021
John Chiminski, Chair And CEO at Catalent (NYSE:CTLT), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030
September 23, 2021
From
Catalent, Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030
September 23, 2021
From
Catalent, Inc.
Via
Business Wire
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
September 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.